Skip to content

GTEN GTEN Change In Deferred Offering Costs

Change In Deferred Offering Costs at other companies

Navan, Inc.
 logo
Navan, Inc. NAVN
$407K
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$164.72K
NetSTREIT logo
NetSTREITNTST
$259K-20.0%
AMB
Ambiq Micro, Inc.AMBQ
-$75K
Jade Biosciences, Inc. Common Stock logo
Jade Biosciences, Inc. Common StockJBIO
$700K
KRAKacquisition
 logo
KRAKacquisition KRAQ
$0

Other financials

Income statement

See full
Operating income-$189.9K-251%
Net income$6.1M+11,475%
EPS (diluted)$0.14+1,500%

Balance sheet

See full
Cash & equivalents$431.3K+15,449%
Total equity-$28.2M-29,913%
Total assets$371.7M+19,333%

Cash flow

See full
Operating cash flow-$188.3K

Valuation

See full
Market cap$470.13M+1.8%
P/E66×

Returns & leverage

See full
Return on equity-50.3%
Current ratio0.3×

Where this comes from

Reported directly by GTEN in its filing.

Tagged under the XBRL concept ck0001986817:ChangeInDeferredOfferingCosts.

The official record: GTEN’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about GTEN's change in deferred offering costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GTEN's change in deferred offering costs?
GTEN (GTEN) reported change in deferred offering costs of $184.67K in Q4 2025.
What does change in deferred offering costs mean?
Tracks the net change in costs incurred in connection with the issuance of equity that are deferred until the offering is completed. Once the offering occurs, these costs are typically reclassified against equity. This metric helps investors track the accumulation of transaction-related expenses before they are finalized on the balance sheet.